Acute modulation of toll-like receptors by insulin

Diabetes Care

Volumn 31, Issue 9, 2008, Pages 1827-1831

  Ghanim, Husam ^a   Mohanty, Priya ^a   Deopurkar, Rupali ^a   Sia, Ching Ling ^a   Korzeniewski, Kelly ^a   Abuaysheh, Sanaa ^a   Chaudhuri, Ajay ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; MESSENGER RNA; METFORMIN; SODIUM CHLORIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR PU 1; ONCOPROTEIN; PROTO ONCOGENE PROTEIN SPI 1; PROTO-ONCOGENE PROTEIN SPI-1; TRANSACTIVATOR PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE CONTROL; GLYCEMIC CONTROL; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MALE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SUPPRESSION, GENETIC; TOLL-LIKE RECEPTORS; TRANS-ACTIVATORS;

EID: 56149118396     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0561     Document Type: Article

References (24)

1. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mono-nuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265, 2001
2. Dandona P, Aljada A, Mohanty P, Ghanim H, Bandyopadhyay A, Chaudhuri A: Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26:3310-3314, 2003
3. Chaudhuri A, Janicke D, Wilson MF, Tri-pathy D, Garg R, Bandyopadhyay A, Cali-eri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P: Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 109:849-854, 2004
4. Visser L, Zuurbier CJ, Hoek FJ, Opmeer BC, de Jonge E, de Mol BA, van Wezel HB: Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normo-glycaemic clamp: effects on inflammatory response during coronary artery surgery. BrJAnaesth 95:448-457, 2005
5. Janssens S, Beyaert R: Role of toll-like receptors in pathogen recognition. Clin Mi-crobiol Rev 16:637-646, 2003
6. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F: Toll-like re-ceptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274:10689-10692, 1999
7. Stoll LL, Denning GM, Weintraub NL: Potential role of endotoxin as a proinflamma-tory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 24:2227-2236, 2004
8. LiH, SunB: Toll-like receptor 4 in atherosclerosis. J Cell Mol Med 11:88-95, 2007
9. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025, 2006
10. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW: Toll like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100:1589-1596, 2007
11. Shishido T, Nozaki N, Takahashi H, Ari-moto T, Niizeki T, Koyama Y, Abe J, Takeishi Y, Kubota I: Central role of endogenous toll-like receptor-2 activationin regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem Biophys Res Commun 345: 1446-1453, 2006
12. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal JF, Thuillez C, Richard V: Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arte-rioscler Thromb Vasc Biol 27:1064-1071, 2007
13. Shishido T, Nozaki N, Yamaguchi S, Shi-bata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M, Takeuchi O, Akira S, Takeishi Y, Kubota I: Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 108:2905-2910, 2003
14. Means TK, Luster AD: Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci 1062:242-251, 2005
15. Zipris D, Lien E, Nair A, Xie JX, Greiner DL, Mordes JP, Rossini AA: TLR9-signal-ing pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 178:693-701, 2007
16. Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Jang E, Lee HA, Youn J, Akira S, Lee MS: Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27:321-333, 2007
17. Haehnel V, Schwarzfischer L, Fenton MJ, Rehli M: Transcriptional regulation of the human toll-like receptor 2 gene in mono-cytes and macrophages. J Immunol 168: 5629-5637, 2002
18. Rehli M, Poltorak A, Schwarzfischer L, Krause SW, Andreesen R, Beutler B: PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J Biol Chem 275:9773-9781, 2000
19. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S: Lipopoly-saccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740-E747, 2007
20. Senn JJ: Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 281:26865-26875, 2006
21. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I: Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflamma-tory state. J Clin Endocrinol Metab 93: 578-583, 2008
22. Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ, Skog-strand K, Hansen TK, Van den Berghe G: Intensive insulin therapy protects the en-dothelium of critically ill patients. J Clin Invest 115:2277-2286, 2005
23. Mizoguchi E, Orihara K, Hamasaki S, Ishida S, Kataoka T, Ogawa M, Saihara K, Okui H, Fukudome T, Shinsato T, Shira-sawa T, Ichiki H, Kubozono T, Ninomiya Y, Otsuji Y, Tei C: Association between toll-like receptors and the extent and severity of coronary artery disease in patients with stable angina. Coron Artery Dis 18:31-38, 2007
24. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Po-lara A, Cobb AJ, Ley SV, AquilinaJA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP: Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217-1221, 2006